AR054632A1 - ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN - Google Patents

ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN

Info

Publication number
AR054632A1
AR054632A1 ARP060102992A ARP060102992A AR054632A1 AR 054632 A1 AR054632 A1 AR 054632A1 AR P060102992 A ARP060102992 A AR P060102992A AR P060102992 A ARP060102992 A AR P060102992A AR 054632 A1 AR054632 A1 AR 054632A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
heterocyclyl
alkyl
aryl
alkylthio
Prior art date
Application number
ARP060102992A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR054632A1 publication Critical patent/AR054632A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ARP060102992A 2005-07-13 2006-07-12 ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN AR054632A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0501663 2005-07-13
SE0502354 2005-10-24

Publications (1)

Publication Number Publication Date
AR054632A1 true AR054632A1 (es) 2007-07-04

Family

ID=37637403

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102992A AR054632A1 (es) 2005-07-13 2006-07-12 ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN

Country Status (15)

Country Link
US (1) US20080312208A1 (enExample)
EP (1) EP1904474A4 (enExample)
JP (1) JP2009501216A (enExample)
KR (1) KR20080039405A (enExample)
AR (1) AR054632A1 (enExample)
AU (1) AU2006267148A1 (enExample)
CA (1) CA2614726A1 (enExample)
EC (1) ECSP088140A (enExample)
IL (1) IL188293A0 (enExample)
MX (1) MX2008000470A (enExample)
NO (1) NO20076682L (enExample)
RU (1) RU2008101924A (enExample)
TW (1) TW200726758A (enExample)
UY (1) UY29667A1 (enExample)
WO (1) WO2007008140A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542641A (ja) * 2006-07-04 2009-12-03 アストラゼネカ アクチボラグ 新規ピリジン類縁体
US20080027104A1 (en) * 2006-07-04 2008-01-31 Astrazeneca Ab Novel Crystalline Forms 2
WO2008085119A1 (en) * 2007-01-12 2008-07-17 Astrazeneca Ab New pyridine analogues viii 518
BRPI0806529A2 (pt) * 2007-01-12 2014-04-22 Astrazeneca Ab Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
TW200833333A (en) * 2007-01-12 2008-08-16 Astrazeneca Ab New pyridine analogues
PE20081892A1 (es) * 2007-07-13 2009-02-21 Astrazeneca Ab Nuevos analogos de amino-piridina como agentes antitromboticos
WO2010005384A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab Ketone pyridine analogues and their use in the treatment of cardiovascular disorders
AR074628A1 (es) * 2008-07-07 2011-02-02 Astrazeneca Ab Derivados de piridina 2- amino-6-alquil sustituidos utiles como inhibidores de p2y12 308
JP2014051434A (ja) * 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
CN103483274B (zh) * 2013-09-25 2016-03-09 江苏快达农化股份有限公司 一种制备苄嘧磺隆的方法
EP3333163A4 (en) 2015-08-06 2019-01-09 UBE Industries, Ltd. SUBSTITUTED GUANIDINE DERIVATIVE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DE60114994T2 (de) * 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
AR037097A1 (es) * 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
KR101010905B1 (ko) * 2002-01-18 2011-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아실아미노티아졸 유도체 또는 그 염
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
AU2004279809B2 (en) * 2003-10-03 2010-07-15 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US20050153077A1 (en) * 2003-12-03 2005-07-14 Anthony Gedeon Method of resisting contaminant build up and oxidation of vehicle surfaces and other surfaces
EA200700117A1 (ru) * 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
BRPI0606437A (pt) * 2005-01-06 2008-03-11 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
CN101511792A (zh) * 2006-07-04 2009-08-19 阿斯利康(瑞典)有限公司 新的吡啶类似物
JP2009542641A (ja) * 2006-07-04 2009-12-03 アストラゼネカ アクチボラグ 新規ピリジン類縁体
CA2655629A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues

Also Published As

Publication number Publication date
WO2007008140A1 (en) 2007-01-18
IL188293A0 (en) 2008-04-13
ECSP088140A (es) 2008-02-20
TW200726758A (en) 2007-07-16
UY29667A1 (es) 2007-02-28
US20080312208A1 (en) 2008-12-18
CA2614726A1 (en) 2007-01-18
KR20080039405A (ko) 2008-05-07
JP2009501216A (ja) 2009-01-15
NO20076682L (no) 2008-03-05
EP1904474A4 (en) 2010-06-16
EP1904474A1 (en) 2008-04-02
AU2006267148A1 (en) 2007-01-18
RU2008101924A (ru) 2009-08-20
MX2008000470A (es) 2008-03-11

Similar Documents

Publication Publication Date Title
AR061651A1 (es) Analogos de piridina ii
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR054632A1 (es) ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN
AR070207A1 (es) Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica
AR040336A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AR060658A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
AR070995A1 (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe
AR056838A1 (es) Derivados de 1,2,5-tiadiazol
AR056548A1 (es) Derivados de sulfonamidas, composiciones farmaceuticas y sus usos
AR057986A1 (es) Compuesto heterociclico y su uso farmaceutico
AR048241A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .
AR051215A1 (es) Derivados de quinazolina
AR069772A1 (es) Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria.
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
AR056109A1 (es) Derivados de tiazolopiridina como activadores de la actividad de glucoquinasa
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
AR079236A1 (es) Derivados de ciclohexano y usos de los mismos
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR035945A1 (es) Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
AR048974A1 (es) Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas.
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal